Expression patterns of microRNA-218 and its potential functions by targeting CIP2A and BMI1 genes in melanoma

Wei, Yanping; Du, Yuwen; Chen, Xiaonan; Li, Ping; Wang, Yuanyuan; Zang, Wenqiao; Zhao, Lindong; Li, Zhongdong

doi:10.1007/s13277-014-2079-6

Cited by 21 publications

(13 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, we confirmed that miR-218, a tumor suppressor in many types of cancers (16)(17)(18), suppressed the expression of MEF2D mRNA by targeting its 3'UTR. In fact, miRNAs have been verified as major regulators of MEF2D expression.…”

Section: Discussionsupporting

confidence: 63%

miR-218 suppresses cardiac myxoma proliferation by targeting myocyte enhancer factor 2D

et al. 2015

View full text Add to dashboard Cite

The role of microRNA-92b-3p (miR-92b-3p) in cardiac hypertrophy was not well illustrated. The present study aimed to investigate the expression and potential target of miR-92b-3p in angiotensin II (Ang-II)-induced mouse cardiac hypertrophy. MiR-92b-3p was markedly decreased in the myocardium of Ang-II-infused mice and of patients with cardiac hypertrophy. However, miR-92b-3p expression was revealed increased in Ang-II-induced neonatal mouse cardiomyocytes. Cardiac hypertrophy was shown attenuated in Ang-II-infused mice received tail vein injection of miR-92b-3p mimic. Moreover, miR-92b-3p inhibited the expression of atrial natriuretic peptide (ANP), skeletal muscle α-actin (ACTA1) and β-myosin heavy chain (MHC) in Ang-II-induced mouse cardiomyocytes in vitro. Myocyte-specific enhancer factor 2D (MEF2D), which was increased in Ang-II-induced mouse hypertrophic myocardium and cardiomyocytes, was identified as a target gene of miR-92b-3p. Functionally, miR-92b-3p mimic, consistent with MEF2D siRNA, inhibited cell size increase and protein expression of ANP, ACTA1 and β-MHC in Ang-II-treated mouse cardiomyocytes. Taken together, we demonstrated that MEF2D is a novel target of miR-92b-3p, and attenuation of miR-92b-3p expression may contribute to the increase of MEF2D in cardiac hypertrophy.

show abstract

Section: Discussionsupporting

confidence: 63%

miR-218 suppresses cardiac myxoma proliferation by targeting myocyte enhancer factor 2D

et al. 2015

View full text Add to dashboard Cite

show abstract

“…For instance, miR-128 acts as a tumor suppressor by directly targeting Bmi1 and CYP2C9 in prostate cancer and hepatocellular carcinoma, respectively (35,36). Bmi1 can be targeted by miR-203, miR-218 and miR-135a in different malignancies (37)(38)(39). Although abundant transcriptional targets are predicted, most of these have not been fully elucidated.…”

Section: Discussionmentioning

confidence: 99%

miR-296-5p suppresses cell viability by directly targeting PLK1 in non-small cell lung cancer

CHEN

et al. 2015

Oncology Reports

View full text Add to dashboard Cite

Polo-like kinase 1 (PLK1), a critical kinase for mitotic progression, is overexpressed in a wide range of cancers. MicroRNAs (miRNAs) are a class of small non-coding RNA molecules and proposed to play important roles in the regulation of tumor progression and invasion. However, the relationship between PLK1 and miRNAs have remained unclear. In the present study, the association between PLK1 and miR-296-5p was investigated. The upregulation of PLK1 mRNA expression levels combined with the downregulation of miR-296-5p levels were detected in both non-small cell lung cancer (NSCLC) tissues and cell lines. Functional studies showed that knockdown of PLK1 by siRNA inhibited NSCLC cells proliferation. Impressively, overexpression of miR-296-5p showed the same phenocopy as the effect of PLK1 knockdown in NSCLC cells, indicating that PLK1 was a major target of miR-296-5p. Furthermore, using western blot analysis and luciferase reporter assay, PLK1 protein expression was proved to be regulated by miR-296-5p through binding to the putative binding sites in its 3'-untranslated region (3'-UTR). Taken together, the present study indicated that miR-296-5p regulated PLK1 expression and could function as a tumor suppressor in NSCLC progression, which provides a potential target for gene therapy of NSCLC.

show abstract

“…Wei et al have reported that miR-218 is downregulated in melanoma cells. miR-218 regulates the proliferation, migration, and invasion of melanoma cell lines A375 and SK-MEL-2 by targeting CIP2A and BMI1, indicating the pivotal role played by miR-218 in melanoma development (Wei et al, 2014). A previous study conducted by Nishikawa et al (2014) revealed a significant inhibition of cancer cell migration and invasion upon restoration of miR-218 in prostate cancer cell lines (PC3 and DU145).…”

Section: Discussionmentioning

confidence: 91%

Reduced miRNA-218 expression in pancreatic cancer patients as a predictor of poor prognosis

2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. microRNA-218 (miR-218) is a vertebrate-specific miRNA that plays a crucial role in tumorigenesis and tumor progression. This study analyzed the miR-218 expression level and clinical significance in pancreatic cancer. One hundred and seven pairs of pancreatic cancer and adjacent normal tissues were analyzed by quantitative reversetranscriptase polymerase chain reaction. The correlation between miR-218 expression and clinicopathological characters was determined by the two-sample Student t-test. The survival correlations were analyzed by the Kaplan-Meier method and Cox proportional hazards model. The relative expression of miR-218 in pancreatic cancer tissues (2.63 ± 1.59) was significantly lower than that in matched noncancerous pancreatic tissues (6.52 ± 2.50, P < 0.001). The low expression of miR-218 in the pancreatic cancer tissues were strongly correlated with the TNM classification (P = 0.02), distant metastasis (P = 0.001), and tumor differentiation (P = 0.003). The low level of miR-218 expression was significantly correlated with the shorter overall survival time of pancreatic cancer patients (5-year overall survival rate: 7.5 vs 34.9%; log-rank test: P < 0.001). Multivariate analyses confirmed that a low level of miR-218 expression was an independent 16373 miR-218 is a prognosis factor for pancreatic cancer ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (4): 16372-16378 (2015) predictor of poor prognosis in pancreatic cancer patients (Hazard ratio: 7.24; 95% confidence interval: 2.01-18.28; P = 0.007). Our findings suggested a significant downregulation in the expression of miR-218; this might have considerable potential value in the prognosis for pancreatic cancer.

show abstract

Expression patterns of microRNA-218 and its potential functions by targeting CIP2A and BMI1 genes in melanoma

Cited by 21 publications

References 34 publications

miR-218 suppresses cardiac myxoma proliferation by targeting myocyte enhancer factor 2D

miR-218 suppresses cardiac myxoma proliferation by targeting myocyte enhancer factor 2D

miR-296-5p suppresses cell viability by directly targeting PLK1 in non-small cell lung cancer

Reduced miRNA-218 expression in pancreatic cancer patients as a predictor of poor prognosis

Contact Info

Product

Resources

About